Prothena Corporation plc Logo

Email this page: News Release

Prothena Presents Compelling New Data From Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis at 2015 ASCO Annual Meeting

For security reasons, registration is required before you can use this feature.
* Indicates required field